Zobrazeno 1 - 6
of 6
pro vyhledávání: '"dabrafenib mesylate"'
Publikováno v:
Crystal Growth & Design. 20:1035-1046
Dabrafenib (DBF) is an anticancer drug with selective B-Raf (BRAF) inhibition activity. In 2013, DBF was approved by the U.S. Food and Drug Administration (US-FDA) as a dabrafenib mesylate salt (DB...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3f3f2137a348e693abd3f95bb66cd3e4
https://doi.org/10.1021/acs.cgd.9b01365
https://doi.org/10.1021/acs.cgd.9b01365
Autor:
Hideaki Sabe, Takashi Yamamoto, Toru Wakamatsu, Satoshi Takenaka, Yoshinori Imura, Shigenori Nagata, Hironari Tamiya, Toshinari Yagi, Katsunari Yamashita
Publikováno v:
Molecular and Clinical Oncology
Malignant gastrointestinal neuroectodermal tumors (GNETs), also called clear-cell sarcoma-like tumors of the gastrointestinal tract, are rare and highly aggressive tumors originating in the gastrointestinal tract. These tumors are generally immunohis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f281da2c89273c0da2eba8500924753c
https://doi.org/10.3892/mco.2020.2185
https://doi.org/10.3892/mco.2020.2185
Publikováno v:
Journal of Oncology
Journal of Oncology, Vol 2019 (2019)
Journal of Oncology, Vol 2019 (2019)
Human organic anion transporter 4 (hOAT4) belongs to a family of multispecific organic anion transporters that play critical roles in the disposition of numerous drugs and therefore are the major sites for drug-drug interaction. Drug-drug interaction
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9630cb99761f46186608fd3334cd19fc
https://doi.org/10.1155/2019/1951786
https://doi.org/10.1155/2019/1951786
Autor:
Daniel A. Hussar, Jessica L. Kaminski
Publikováno v:
Journal of the American Pharmacists Association : JAPhA. 53(5)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1a30553582888a4326cdb15b3c5f3b1
https://pubmed.ncbi.nlm.nih.gov/24030134
https://pubmed.ncbi.nlm.nih.gov/24030134
Autor:
Rachael Anforth, Alexander M. Menzies, Giuliana Carlos, Pablo Fernandez-Penas, Arthur Clements, Matteo S. Carlino, Shaun Chou
Publikováno v:
JAMA Dermatology. 151:1103
The cutaneous adverse effects of the BRAF inhibitors vemurafenib and dabrafenib mesylate in the treatment of metastatic melanoma have been well reported. The addition of a MEK inhibitor to a BRAF inhibitor improves the blockade of the mitogen-activat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8afa3a947ae6e9da0cf807f009deb418
https://doi.org/10.1001/jamadermatol.2015.1745
https://doi.org/10.1001/jamadermatol.2015.1745
Autor:
Yagi T; Department of Outpatient Chemotherapy, Osaka International Cancer Institute, Osaka 541-8567, Japan., Nagata S; Department of Diagnostic Pathology and Cytology, Osaka International Cancer Institute, Osaka 541-8567, Japan., Yamamoto T; Department of Clinical Laboratory, Osaka International Cancer Institute, Osaka 541-8567, Japan., Wakamatsu T; Department of Orthopedic Surgery, Osaka International Cancer Institute, Osaka 541-8567, Japan., Imura Y; Department of Orthopedic Surgery, Osaka International Cancer Institute, Osaka 541-8567, Japan., Tamiya H; Department of Orthopedic Surgery, Osaka International Cancer Institute, Osaka 541-8567, Japan., Sabe H; Department of Orthopedic Surgery, Osaka International Cancer Institute, Osaka 541-8567, Japan., Yamashita K; Department of Orthopedic Surgery, Osaka International Cancer Institute, Osaka 541-8567, Japan., Takenaka S; Department of Orthopedic Surgery, Osaka International Cancer Institute, Osaka 541-8567, Japan.
Publikováno v:
Molecular and clinical oncology [Mol Clin Oncol] 2021 Feb; Vol. 14 (2), pp. 23. Date of Electronic Publication: 2020 Dec 04.